Artixio

Biologics Regulatory Affairs Services — Global Support

From early-stage development to global market access, we help biologic products meet country-specific requirements with clarity and confidence.
Biologics demand a different level of regulatory attention. From product characterization and comparability studies to post-market obligations, each step is bound by region-specific protocols. At Artixio, we work closely with companies developing monoclonal antibodies, vaccines, cell and gene therapies, or biosimilars, offering regulatory guidance shaped by science, precision, and country requirements.
Whether you’re preparing for FDA’s BLA pathway, EMA’s centralized procedure, or gaining acceptance in APAC, MENA, or LATAM regions, we help you align your product with the local authorities’ expectations — without slowing down your launch timelines.

Regulatory Affairs Lifecycle for Biologics

Pre-Development Advisory
Identify target market-specific requirements early
Product Characterization & Dossier Planning
Align studies, comparability, and data with regional needs
Regulatory Submissions
Prepare CTD, eCTD or other required formats
Authority Communication & Response Management
Handle queries, deficiencies, and updates promptly
Market Authorization & Launch Readiness
Support labeling, packaging, and final review steps
Post-Market Compliance & Reporting
Safety data, variations, renewals, and lifecycle tracking

Why Artixio for Biologics Regulatory Affairs

15–35 years of cross-functional experience in biologics regulation, CMC strategy, and global submissions
Specialized teams for FDA, EMA, PMDA, and other regional pathways
Real-time coordination with CMC, clinical, and safety stakeholders
Documentation built from scientific evidence, not templates
Proven record in managing centralized, hybrid, and national procedures
Global delivery with local regulatory insight
Integrated support for both development-stage and commercial-stage biologics
Personalized communication and dedicated project ownership

FAQs

1. What is the difference between drug and biologic regulation globally?
Biologics are regulated through separate agencies or divisions within regulatory bodies due to their complexity, variability, and production methods. Requirements around characterization, stability, and comparability are far more detailed than for small molecules.
Yes, we handle a wide range of biologics, including ATMPs (Advanced Therapy Medicinal Products) such as gene therapies, CAR-T cells, and stem cell-based treatments.
We help with data bridging, justification strategies, and comparability assessments for biosimilars across US, EU, and other major markets. We also support local requirements in emerging markets.
Yes, our team can coordinate simultaneous submissions through a unified strategy while aligning with each authority’s documentation preferences and timelines.
We manage variations, renewals, safety reports, and manufacturing changes across different health authorities so your approvals remain active and compliant.

Still Have Questions ?

Get expert answers tailored to your needs.

Specialized Regulatory Affairs Services Across Multiple Industries

Pharmaceuticals

MedTech

Cosmetics

Nutrition

Biologics

Veterinary

Expert Regulatory Services To Streamline Compliance

Regulatory Intelligence & Strategy
Medical & Technical Writing
Publishing & Submission
Product Registration
Investigation New Drug Application (IND)
New Drug Application (NDA)
Post Approval Lifecycle Maintenance
Artwork and Label Review
Ad Promo Review

Regulatory Affairs Across Multiple Countries

India

Singapore

Mexico

Brazil

Vietnam

Malaysia

Argentina

Colombia

Taiwan

China

Europe

Thailand

Indonesia

Philippines

USA

Japan

Qatar

South Korea

Insights from Artixio - Tips & Articles

In Vitro Diagnostics: Meaning, Types And Benefits

In Vitro Diagnostics: Meaning,

The term “in vitro” is a Latin word that means “in glass”. Thus, from...

June 20, 2025
IVD Medical Devices Registration & Approval In India

IVD Medical Devices Registration

The in vitro diagnostic in India is regulated by the Central Drugs Standard Control...

June 17, 2025
Pharma Manufacturing Booms in Hidalgo, Mexico

Pharma Manufacturing Booms in

Once overlooked pharma hub in Mexico's Hidalgo region has gained importance with global market...

June 18, 2025